Rafferty Asset Management
KNSA icon

Rafferty Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Rafferty Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,614
Closed -$1.13M – 1171
2024
Q2 		$1.13M Sell
60,614
-80,249
-57% -$1.5M ﹤0.01% 789
2024
Q1 		$2.78M Buy
140,863
+45,008
+47% +$879K 0.01% 607
2023
Q4 		$1.68M Sell
95,855
-43,251
-31% -$711K 0.01% 716
2023
Q3 		$2.42M Buy
139,106
+19,731
+17% +$332K 0.01% 560
2023
Q2 		$1.68M Sell
119,375
-9,913
-8% -$133K 0.01% 690
2023
Q1 		$1.39M Buy
129,288
+37,976
+42% +$500K 0.01% 714
2022
Q4 		$1.37M Buy
+91,312
New +$1.33M 0.01% 681
2022
Q1 		– Sell
-88,024
Closed -$1.04M – 1279
2021
Q4 		$1.04M Buy
88,024
+1,819
+2% +$22.4K 0.01% 847
2021
Q3 		$982K Sell
86,205
-16,876
-16% -$220K 0.01% 829
2021
Q2 		$1.44M Buy
103,081
+38,673
+60% +$587K 0.01% 776
2021
Q1 		$1.19M Buy
64,408
+47,641
+284% +$974K 0.01% 732
2020
Q4 		$296K Buy
+16,767
New +$295K ﹤0.01% 812

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Rafferty Asset Management's KNSA Position: Q3 2024 in Review

Rafferty Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2024, closing a stake of 60,614 shares — an estimated $1.13M sold.

Rafferty Asset Management first reported a position in KNSA in Q4 2020 and held it in 12 quarters. The position peaked at $2.78M in Q1 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

  • Rafferty Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 60,614 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $1.13M.
  • Rafferty Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Rafferty Asset Management's Kiniksa Pharmaceuticals position peaked at $2.78M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.